<DOC>
	<DOCNO>NCT01572675</DOCNO>
	<brief_summary>This postmarketing study examine use etoricoxib ( Arcoxia® ) routine clinical practice France well use celecoxib ( Celebrex® ) .</brief_summary>
	<brief_title>A Study Patterns Use Etoricoxib France ( MK-0663-148 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<criteria>Treatmentnaive , discontinue previous treatment course etoricoxib celecoxib least 3 month previously currently receive continuous treatment oral etoricoxib celecoxib Consent take part study Included his/her physician 's client base least 1 year Unable receive followup year Included interventional trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pharmacoepidemiological</keyword>
	<keyword>Longitudinal</keyword>
	<keyword>Observational</keyword>
</DOC>